{"id":"NCT04594213","sponsor":"Merz North America, Inc.","briefTitle":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","officialTitle":"A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-23","primaryCompletion":"2021-04-15","completion":"2022-05-09","firstPosted":"2020-10-20","resultsPosted":"2024-05-08","lastUpdate":"2024-05-08"},"enrollment":362,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)"],"interventions":[{"type":"DRUG","name":"NT 201","otherNames":["IncobotulinumtoxinA","Xeomin","Botulinum toxin type A (150 kiloDalton), free from complexing protein"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Main Period: Placebo (Group P)","type":"PLACEBO_COMPARATOR"},{"label":"Main Period: NT 201 (Group U)","type":"EXPERIMENTAL"},{"label":"Main Period: NT 201 and Placebo (Group G and H)","type":"EXPERIMENTAL"},{"label":"OLEX: NT 201 (Main Period: Group P)","type":"EXPERIMENTAL"},{"label":"OLEX: NT 201 (Main Period: Group U)","type":"EXPERIMENTAL"},{"label":"OLEX: NT 201 (Main Period: Group G and H)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial Lines \\[UFL\\]): Horizontal Forehead Lines \\[HFL\\], Glabellar Frown Lines \\[GFL\\], and Lateral Canthal Lines \\[LCL\\]). It is a prospective, randomized, double-blind, placebo-controlled, multicenter study with a placebo-control main period (MP) followed by an open-label extension (OLEX) period.","primaryOutcome":{"measure":"Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30","timeFrame":"Day 30","effectByArm":[{"arm":"Main Period: Placebo (Group P)","deltaMin":0,"sd":null},{"arm":"Main Period: NT 201 (Group U)","deltaMin":52.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["39475143"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":91},"commonTop":["COVID-19","Blood pressure increased","Injection site bruising"]}}